OPEXA THERAPEUTICS INC (OPXA)

Overview Price 0.97 Price Change Today -$0.03 (-3.00%) P&P rating Zacks Rank N/A - N/A Open Price $0.99 Previous Close $1.00 Daily Range $0.96 - $0.99 52-Week Range $0.89 - $2.30 Volume 53,290 Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes. Other Resources for OPXA Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary No Commentary Found for This Ticker. Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes.   Brokerage Analyst Recommendations 1 Brokerage Firms Covering OPXA   Strong Buy 1 Buy 0 Hold 0 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1   OPXA Ratings: BUY  SELL  HOLD OPXA Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 0 Buy 0 Sell   Top Buy Analysis No Buy Analysis. Be the First. More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
AndrewGreenBull	97.65	11/13/09	DARA—Time to Harvest	2	11/13/09

Commentary

There are no open picks with this stock at the moment.

Picks

There are no open picks with this stock at the moment.